The Cost-Effectiveness of Bendamustine-Rituximab Versus Fludarabine-Rituximab for Patients with Indolent Non-Hodgkin’s Lymphoma (INHL) Who Have Progressed Following Treatment with Rituximab or a Rituximab-Containing Regimen in Mexico
Abstract
Authors
D. Bertwistle J. Munakata E. Wehler V. Leyva A. Valencia A. Hernandez L. de la Torre L. Gonzalez